LSTA1 helps activate a new uptake pathway that enables co-administered or tethered anti-cancer drugs to penetrate solid tumours. Credit: Nemes Laszlo / Shutterstock.com.

Lisata Therapeutics has received orphan drug designation from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products for LSTA1 to treat pancreatic cancer.

LSTA1 is an investigational drug designed to activate a new uptake pathway that enables co-administered or tethered anti-cancer drugs to penetrate solid tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug actuates this targeted transport system within tumours, leading to the penetration and build-up of co-administered anti-cancer drugs throughout the body.

LSTA1 may alter the tumour microenvironment, making tumours more susceptible to immunotherapies.

It is currently undergoing multiple clinical studies worldwide across solid tumour types, including pancreatic cancer, along with diverse anti-cancer regimens.

Lisata, with its partners, has gathered non-clinical data showing improved delivery of established and emerging cancer treatments such as immunotherapy, chemotherapy and RNA-based therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LSTA1 has shown promising safety, activity and tolerability in clinical trials, improving the administration of standard-of-care chemotherapy for pancreatic cancer.

Lisata chief medical officer and research and development executive vice-president Kristen Buck stated: “To date, LSTA1 has demonstrated favourable safety, tolerability and activity to enhance delivery of standard-of-care chemotherapy for patients with metastatic pancreatic cancer.

“Obtaining orphan drug designation from the EMA reinforces our belief that LSTA1 offers a major improvement in treating patients with this terrible disease.

“We are excited by the promise of LSTA1 for the treatment of pancreatic cancer and other solid tumours and are committed to advancing our development programmes with the goal of providing a benefit to patients.”